Literature DB >> 19166965

Integrin cleavage facilitates cell surface-associated proteolysis required for vascular smooth muscle cell invasion.

Kai Kappert1, Heike Meyborg, Bernadette Baumann, Vesna Furundzija, Jan Kaufmann, Kristof Graf, Dietger Stibenz, Eckart Fleck, Philipp Stawowy.   

Abstract

Vascular smooth muscle cell (VSMC) invasion is a key element in atherogenesis and restenosis, requiring integrins for adhesion/de-adhesion as well as matrix metalloproteinases (MMPs) for focalized proteolysis. Among the MMP family, pro-MMP-2 is unique in its activation, depending on the formation of a multiprotein complex with MT1-MMP/TIMP-2 at the cell surface, in which integrin alphavbeta3 participates. Integrin alphav and MT1-MMP are synthesized from precursors via furin-dependent cleavage of their pro-peptide. Furin is the prototypical proprotein convertase highly expressed in VSMCs and human atherosclerotic lesions. Its precise role in the tight network involving MMPs/integrins and their coordination and cooperation required for VSMC invasion is unknown. We demonstrate that furin-inhibition with decanoyl-RVKR-chloromethylketone inhibits VSMC invasion in a comparable degree to MMP inhibitors, which reduce the MT1-MMP-MMP-2 proteolytic cascade. Furin-inhibition did not prevent MT1-MMP/MMP-2 maturation. In contrast, it strongly reduced pro-alphav cleavage, but did not lessen its cell membrane expression. However, inhibition of pro-alphav processing via furin-inhibition strongly reduced pro-MMP-2 binding to the cell surface, thereby lessening its full maturation and diminishing the cell surface in situ proteolysis required for invasion. Thus, our data demonstrate a novel mechanism of furin-dependent alphav cleavage that enhances pro-MMP-2 binding and activation at the cell membrane in cooperation with MT1-MMP in primary VSMCs. Processing of alphav by furin contributes to the recruitment of enzymatic energy to the cell surface, thereby providing focalized proteolysis associated with VSMC invasion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19166965     DOI: 10.1016/j.biocel.2009.01.004

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  6 in total

1.  Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation.

Authors:  Amanda Soler; Ian Hunter; Gregory Joseph; Rebecca Hutcheson; Brenda Hutcheson; Jenny Yang; Frank Fan Zhang; Sachindra Raj Joshi; Chastity Bradford; Katherine H Gotlinger; Rachana Maniyar; John R Falck; Spencer Proctor; Michal Laniado Schwartzman; Sachin A Gupte; Petra Rocic
Journal:  J Mol Cell Cardiol       Date:  2018-02-08       Impact factor: 5.000

2.  Id4 suppresses MMP2-mediated invasion of glioblastoma-derived cells by direct inactivation of Twist1 function.

Authors:  G J Rahme; M A Israel
Journal:  Oncogene       Date:  2014-01-13       Impact factor: 9.867

3.  Furin Functions as a Nonproteolytic Chaperone for Matrix Metalloproteinase-28: MMP-28 Propeptide Sequence Requirement.

Authors:  Maria Pavlaki; Stanley Zucker; Antoine Dufour; Nikki Calabrese; Wadie Bahou; Jian Cao
Journal:  Biochem Res Int       Date:  2010-11-01

4.  Influence of a Coronary Artery Disease-Associated Genetic Variant on FURIN Expression and Effect of Furin on Macrophage Behavior.

Authors:  Guojun Zhao; Wei Yang; Jingchun Wu; Bairu Chen; Xu Yang; Junhui Chen; David G McVey; Catherine Andreadi; Peng Gong; Tom R Webb; Nilesh J Samani; Shu Ye
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-08       Impact factor: 8.311

5.  Integrin-specific control of focal adhesion kinase and RhoA regulates membrane protrusion and invasion.

Authors:  Patricia Costa; Tim M E Scales; Johanna Ivaska; Maddy Parsons
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

Review 6.  Left Distal Transradial Approach for Coronary Intervention: Insights from Early Clinical Experience and Future Directions.

Authors:  Hao Feng; Zhenfei Fang; Shenghua Zhou; Xinqun Hu
Journal:  Cardiol Res Pract       Date:  2019-10-31       Impact factor: 1.866

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.